Race Oncology Limited

ASX:RAC

Race Oncology Limited

ASX:RAC
TradeAdd trade order Follow Unfollow Set Price Alert
$1.420 (-3.1%)
Last close price
#173
Rank
1
Held by
8
Followers
TradeAdd trade order Follow Unfollow Set Price Alert
Reports (1) My Report Forum Investors
Top member reports
Consensus
No meetings
Consensus community valuation
The consensus valuation is for members only and has been removed from this chart. Click for membership options.
Become a member
Contributing Members
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
Become a member
#ASX Announcements
stale
Garfield
Added 8 months ago
View author's company report

Couple of bag-holders still in this I think. I hold a little IRL no on SM. Could be a good sign:


Dear investor,

 

We are pleased to announce that a Certificate of Analysis (CoA) has been issued by Ardena for the first current Good Manufacturing Practice (cGMP) batch of our proprietary bisantrene formulation, RC220, confirming that the drug product meets the quality specifications required for human use. 

 

Our innovative RC220 formulation has been designed to enable safe administration of bisantrene to patients via peripheral vein (arm or leg) intravenous (IV) infusions. The CoA confirms that RC220 meets the manufacturing quality specifications required for IV drug products to be used in humans. Adherence to cGMP quality standards meets the requirements for evaluating new IV drug products in human Phase 1 & 2 clinical studies in Asia-Pacific, Europe and the USA.

 

Reaching this point in the development of bisantrene is a major milestone and is a testament to the dedication and skill of the Race team. We are now looking forward to completing the GLP toxicology testing of RC220 in the coming months and beginning the clinical program that will give patients access to bisantrene in a format that is both easier and safer to use.

 

For more information, please refer to our ASX Announcement here.

 

Best Regards,

 

Dr Daniel Tillett

Chief Executive Officer

Read More
Valuation of $4.75
stale
Quiltman
Edited 3 years ago

A breakthrough chemotherapy heart protection discovery was announced yesterday for Zantrene. Much of the focus has been on the FTO pathway, however this cardio-protection is a novel use of Zantrene independent of its ability to target FTO in cancer. Zantrene has been shown in preclinical studies to protect human heart muscle cells from anthracycline-chemotherapy induced cell death. Anthracyclines are highly effective anti-cancer drugs, but their use in patients comes with the serious risk of permanent damage to the heart. In addition, Zantrene synergises with existing anthracyclines to better kill breast cancer cells ( the study was done on breast cancer). This opens an enormous commercial pathway for Race via Zantrene/anthracycline formulations and combinations.

This has the potential to complement existing oncology treatment protocols for better patient outcomes, and will potentially allow oncologists to up dosage on the anthracycline being used, a proven cancer killer. The commercial implications of this are far reaching for Zantrene. Phase 2B clinical studies will be conducted next year.

....

Next Short term target after hitting $3.50 is $4.50. Excellent preclinical results for Ovarian Cancer treatment were announced out of Newcastle University for Bisantrene. This will soon be followed by Breast Cancer preclinical results soon. FTO pathway to be announced by end of March, re-iterated in Half Yearly , which will add a massive second bow to Bisantrene. I fully expect that this amazing drug will be acquired by a large pharmaceutical company within the next 2 years, most likely before phase 2 clinical trials have even started. An amazing story of a "lost" drug with 40 years of research behind it and among many things, a legacy of treated cancer survivors.

Read More